Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

OBJECTIVE: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer. METHODS: Patients with HER2-negative breast cancer, who were pre-treated with anthracycline or taxanes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Nanlin, Si, Yiran, Yue, Jian, Sun, Tingting, Wang, Xue, Jia, Zhuqing, Gao, Songlin, Li, Qiao, Shao, Yang, Wang, Jiayu, Luo, Yang, Ma, Fei, Xu, Binghe, Yuan, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330540/
https://www.ncbi.nlm.nih.gov/pubmed/33710812
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330540/
https://www.ncbi.nlm.nih.gov/pubmed/33710812
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0463

Ejemplares similares